| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9036c33bbe3f4ea428655b76200f7c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-464
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate |
1993-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ad52fb4db77e3198fd2fd4bed8003e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_942e6b3cbe8caa23268233261ae03eaa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72510013585d16b68f76303001a1db87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8437995695b67aec6d042cedd0bcd7c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_045b8818c62817bc420a19784de9d367
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c77936fce552d2606835f91c46d9f71 |
| publicationDate |
1994-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0598998-A2 |
| titleOfInvention |
Humanized antibodies reacting with the ganglioside GM2 |
| abstract |
Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM 2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM 2 . n In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0882794-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0882794-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008090960-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0123431-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-751948-B2 |
| priorityDate |
1992-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |